Blueprint Medicines

Blueprint Medicines offers a 2-year Fellowship Program in collaboration with Northeastern University designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Blueprint Medicines is a global precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines.

Blueprint Medicines is currently recruiting for a two year post-PharmD fellowship in Global Medical Affairs. Applicants are strongly encouraged to submit application materials (Curriculum vitae, Unofficial PharmD transcripts, Cover letter) by the priority deadline of April 8th, 2022.

Recruitment for the 2022-24 Blueprint Medicines Global Medical Affairs Fellowship position has ended.

LEARN ABOUT BLUEPRINT MEDICINES

BLUEPRINT MEDICINES BROCHURE

X4 Pharmaceuticals

X4 Pharmaceuticals offers a two year post-PharmD fellowship in Global Medical Affairs in collaboration with Northeastern University. The fellowship program is designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting.

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system via antagonism of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. We believe that inhibition of the CXCR4 receptor creates the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Our lead clinical candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. We are currently evaluating the safety and efficacy of mavorixafor in a Phase 3 clinical trial for the treatment of patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. To date, mavorixafor has demonstrated proof-of-concept in WHIM syndrome in a Phase 2 clinical trial, including clinically meaningful increases in neutrophil and lymphocyte biomarker counts, as well as a trend of reduction in infection rates and wart burden, and has been generally well tolerated. Enrollment in the Phase 3 WHIM clinical trial is now complete and top-line clinical results are expected in the fourth quarter of 2022. For the WHIM indication, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Designation in the U.S., and Orphan Drug Status in both the U.S. and European Union.

We are also studying mavorixafor in two Phase 1b clinical trials – one in combination with ibrutinib in patients with a rare B-cell lymphoma called Waldenstrom macroglobulinemia, and the other as a monotherapy in patients with Severe Congenital Neutropenia (SCN) and other chronic neutropenia disorders.

LEARN ABOUT X4 PHARMA

Recruitment for the 2022-24 X4 Global Medical Affairs Fellowship position has ended.

Alkermes

This two-year Fellowship Program in collaboration with Northeastern University and Alkermes plc is designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Alkermes has a diversified portfolio of commercially available medications and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders (e.g. addiction, schizophrenia) and oncology.

Alkermes Medical Affairs strives to educate healthcare communities and decision makers on the value of our products through the generation and dissemination of scientifically rigorous, accurate, and unbiased clinical, economic, and health outcomes information, with the goal of advancing healthcare. We accomplish this by partnering with internal Alkermes colleagues to catalyze science and knowledge and by serving as a bridge between Alkermes and the healthcare community.

Unfortunately, we are no longer recruiting for the Alkermes 2022-24 post-PharmD fellowship in Medical Affairs.

Alnylam Pharmaceuticals

In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotations. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting.

The Fellowship Program proudly offers 2-year positions in the following expertise areas: Global Medical Information, Global Medical Publications, Global Safety, Marketing, Regulatory Affairs, and Value and Evidence Strategy (VEST).

LEARN ABOUT ALNYLAM

ALNYLAM FELLOWSHIP BROCHURE

2022-24 Alnylam Fellowship positions has been filled.

AMRYT PHARMA

Amryt is a global commercial-stage biopharmaceutical company dedicated to developing and delivering innovative new treatments to help improve the lives of patients with rare and debilitating diseases. A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity, and ethical practice. Our exceptional team offers a wealth of experience in identifying, commercializing, and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals and get our life changing medicines to all those who need them.

Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt’s commercial business comprises three orphan disease products – metreleptin (Myalept®/ Myalepta®); octreotide (Mycapssa®); and lomitapide (Juxtapid®/ Lojuxta®). Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE®) technology platform.

Amryt offers a two year post-PharmD fellowship in Medical Affairs.

LEARN ABOUT AMRYT

AMRYT FELLOWSHIP BROCHURE

2022-24 AMRYT Fellowship position has been filled.

Eidos Therapeutics, a subsidiary of BridgeBio Pharma

Eidos Therapeutics/BridgeBio Pharma offers a 2-year Fellowship Program in collaboration with Northeastern University designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Eidos is a clinical-stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our product candidate, acoramidis (AG10), is an orally-administered small molecule designed to potently stabilize TTR, a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs.

Eidos Therapeutics/BridgeBio Pharma offers a two year post-PharmD fellowship in Regulatory Affairs.

LEARN ABOUT BRIDGEBIO

2022-24 Eidos Therapeutics/BridgeBio Pharma Fellowship position has been filled.

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a commercial biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates in clinical studies, QINLOCK® is Deciphera’s first FDA-approved drug, a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK®, an oral oncolytic, is also approved in Canada, Australia, Hong Kong, Taiwan, and China for the treatment of fourth-line GIST.

Our Science and Our Pipeline:

Deciphera is developing novel small molecule drug candidates to improve the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the effectiveness of many cancer therapies. Our pipeline of drug candidates is designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes called kinase. Enabled by our proprietary kinase switch control inhibitor drug discovery platform, we have developed kinase switch control inhibitors that interact at a molecular level in a way that is distinct from other kinase inhibitors and are designed to generate higher and more durable rates of response.

We have developed a diverse pipeline of differentiated, orally administered, oncology drug candidates that includes, among others, our approved product, QINLOCK (ripretinib), a broad-spectrum KIT and PDGFRA kinase switch control inhibitor is approved for the treatment of fourth-line GIST. Our follow-on study of ripretinib, the INTRIGUE study, is a pivotal Phase 3 trial in second-line GIST. We also have three additional clinical-stage programs for drug candidates DCC-3116, vimseltinib, and rebastinib. Several research-stage programs are in the pipeline as well.

Unfortunately, we are no longer recruiting for the Deciphera 2022-24 post-PharmD fellowship position in Medical Affairs.

Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

Dyne Therapeutics offers a two year post-PharmD fellowship in Regulatory Affairs and Pharmacovigilance.

LEARN ABOUT DYNE

2022-24 Dyne Therapeutics Fellowship position has been filled.

Flatiron Health, Inc

Flatiron Health, Inc.® is a health tech company founded in 2012 and is a world leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in care and treatments for patients with cancer. We translate patient experiences into real-world evidence (RWE) to improve treatment, inform policy, and advance research. Our unparalleled network supports physicians and other healthcare professionals on the cancer frontlines, and can connect clinical practices and patients directly to research that can expand and improve treatment and care options in oncology.
We provide technology and services that help community oncology centers deliver better patient experiences, operate healthier practices and facilitate clinical research. We ensure that the experiences of millions of people living with cancer are included in the research and decisions that can help patients, as only approximately 5 percent of patients with cancer are represented in randomized clinical trials. We securely de-identify, aggregate and analyze patient data to unlock new understandings of disease and treatment patterns to inform clinical care, research, and regulatory decisions that extend options to patients and healthcare providers.

In partnership with Northeastern University, Flatiron Health is introducing a two-year PharmD Regulatory Affairs fellowship based at the New York City headquarters. The fellowship will provide PharmD graduates with a unique opportunity to gain exposure to the rapidly evolving RWD/E regulatory landscape. The Regulatory Affairs fellow may work on the Regulatory Strategy and Regulatory Policy teams, with potential opportunities to rotate to other functional areas based on personal interest and company demand.

LEARN ABOUT FLATIRON

FLATIRON FELLOWSHIP BROCHURE

2022-24 Flatiron Health, Inc.® Fellowship position has been filled.

Flexion Therapeutics

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.

We embrace a philosophy of scientific entrepreneurship which spurs innovation and empowers and inspires our people to discover, develop and commercialize transformative therapies which can make a meaningful difference in the lives of patients.

The Flexion Medical Affairs team is dedicated to identifying, generating, communicating and gathering scientific knowledge of musculoskeletal conditions as trusted scientific colleagues and strategic business partners, ultimately improving the management of patients with these conditions.

LEARN ABOUT FLEXION

There are no positions available for the 2022-24 Fellowship cycle.

Back to top

GSK

GSK Oncology is committed to the discovery and development of new and potentially life-changing therapies for patients with cancer. Our vision is for people with cancer to not only to live, but to live well, because we are delivering innovative and transformational medicines. GSK’s approach to oncology is focused on innovation in the areas of immuno-oncology, cell therapy, tumor cell targeting and synthetic lethality.

GSK offers two year post-PharmD fellowships in Global Scientific Communications and Global Medical Information.

LEARN ABOUT GSK

GSK FELLOWSHIP BROCHURE

2022-24 GSK Oncology Fellowship position has been filled.

IPSEN

Ipsen Biopharmaceuticals, Inc. is launching a 2-year post-PharmD fellowship in U.S. Medical Affairs in collaboration with Northeastern University, School of Pharmacy.

Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.

LEARN ABOUT IPSEN
IPSEN FELLOWSHIP BROCHURE

2022-24 IPSEN Fellowship position has been filled.

Seqirus

Seqirus. plans to launch a 2-year post-PharmD fellowship in collaboration with Northeastern University, School of Pharmacy.

Derived from the expression ‘securing health for all of us’, Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic and we have been committed to the fight against influenza ever since.

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.

Our vision is a world protected from influenza.

LEARN ABOUT SEQIRUS

2022-24 SEQIRUS Fellowship position has been filled.

Takeda Pharmaceutical Company

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.

Takeda has presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third and first largest pharmaceutical markets in the world. Takeda will deliver highly innovative medicines and transformative care for more people globally.

Takeda offers 2 year post-PharmD fellowships in Medical Affairs.

LEARN ABOUT TAKEDA

TAKEDA FELLOWSHIP BROCHURE

2022-24 Takeda Fellowship position has been filled.

Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 2,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development.
Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal.

Vertex offers a variety of 2-year post-PharmD fellowships in Clinical Pharmacology, Global Safety, Global Medical Affairs, Regulatory Affairs, Clinical Scientist, and Medical Writing in collaboration with Northeastern University’s School of Pharmacy.

LEARN ABOUT VERTEX

VERTEX FELLOWSHIP BROCHURE

2022-24 Vertex Fellowship positions have been filled.